Article

Daily Medication Pearl: Capecitabine (Xeloda)

Capecitabine (Xeloda) is indicated for adjuvant colon cancer, metastatic colorectal cancer, and metastatic breast cancer.

Medication Pearl of the Day: Capecitabine (Xeloda)

Indication: Capecitabine (Xeloda) is a nucleoside metabolic inhibitor with antineoplastic activity indicated for adjuvant colon cancer, metastatic colorectal cancer, and metastatic breast cancer.

Insight:

  • Dosing: Monotherapy 1250 mg/m2 twice daily orally for 2 weeks followed by a 1-week rest period in 3-week cycles.
  • Dosage forms: Tablets 150 mg and 500 mg.
  • Adverse events: Most common adverse reactions (≥30%) were diarrhea, hand-and-foot syndrome, nausea, vomiting, abdominal pain, fatigue/weakness, and hyperbilirubinemia. Other adverse reactions, including serious adverse reactions, have been reported
  • Mechanism of action: Enzymes convert capecitabine to 5-fluorouracil (5-FU) in vivo. Both normal and tumor cells metabolize 5-FU to 5-fluoro-2’-deoxyuridine monophosphate and 5-fluorouridine triphosphate. These metabolites cause cell injury by 2 different mechanisms.

Source: XELODA (capecitabine) tablets, for oral use (fda.gov)

Related Videos
Happy elderly patient with medical health checkup with cardiologist or geriatric doctor. Senior old aging woman with coronary artery heart disease or cardiac illness check-up in clinic - Image credit: Chinnapong | stock.adobe.com
Pharmacist and patient in a retail/community pharmacy setting -- Image credit: Zamrznuti tonovi | stock.adobe.com
Menoapuse spelled with wooden blocks -- Image credit: loran4a | stock.adobe.com